When will the takeover happen?

Discussion in 'GlaxoSmithKline' started by anonymous, Sep 4, 2015 at 6:33 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    ........don't we all ?
     

  2. anonymous

    anonymous Guest

    Watch the change in tone on Wednesday's earning call regarding GSK's commitment to R&D in pharmaceuticals. CEO under obvious pressure from Board Chairman Hampton to reverse the bizarre decision to sell the oncology franchise as well as embrace the "volume" strategy with consumer staples and vaccines. Look for leadership change in Dec. GSK stock to rally.
     
  3. anonymous

    anonymous Guest

    Interesting article. Here's part of the article for those interested. Take a look at the last sentence. Witty is being bypassed. Folks are going straight to Hampton. A clear sign that Witty's days are coming to an end.

    Inside U.K. biopharma circles, you can find few people more influential than veteran fund manager Neil Woodford. He helped AstraZeneca beat back Pfizer's takeover attempt. And at a crucial point last year, Woodford provided some much needed confidence in GlaxoSmithKline as he voiced his approval of the company's strategic direction in the face of its eroding financial performance and sliding share price.

    Now, at least as far as long-suffering GSK is concerned, that confidence appears to have run thin after Woodford has begun to campaign for the pharma giant to formally explore a breakup, according to a report from Sky News. If it does spin out its consumer, HIV (the joint venture Viiv) and dermatology businesses, the move to concentrate on pharma/vaccines would shine an even brighter light on the company's poor pipeline performance and questionable future in drug development.

    According to press reports Woodford has been huddling with GSK Chairman Philip Hampton, rather than CEO Andrew Witty, who has seen the share price decline as hard competition to its flagship drug franchise for Advair slowly takes shape.
     
  4. anonymous

    anonymous Guest

    oh my !
     
  5. anonymous

    anonymous Guest

    Top shareholders will meet with Board members at almost every public company. Same goes with the investment banks.

    Thanks for wasting our time.
     
  6. anonymous

    anonymous Guest

    Yes idiot, but they don't jump over the CEO and go straight to the Board Chair. You must be the GSK-hired troll. Hopefully you'll be the first one sacked. I hear bootlickers are needed in the House of Lords and US Congress. Better get your resume submitted now.
     
  7. anonymous

    anonymous Guest

    Sorry to disappoint you Skippy the troll, but banks and shareholders meet with Board members all the time and they don't ask the CEO for permission. Have you ever read proxy statements from M&A deals. In the majority of cases, the approach was made to the Chairman of the Board and NOT the CEO.
     
  8. anonymous

    anonymous Guest

    OK Wall Street and corporate governance wizards, quiet down. The losmapimod cardiovascular study announcement is disappointing news but was high risk/high reward so negative news was a probable outcome. The study results for the shingles vaccine in pts >70 yrs age is spectacular news. The previous results were even more spectacular (98% efficacy) in younger pts and the company indicates they will file in the latter part of 2016. This will easily be a billion dollar product and will be administered at local pharmacies and doctor's offices. This is the kind of breakthrough GSK needs.

    The chatter about breaking the company apart is just that, chatter.
     
  9. anonymous

    anonymous Guest

    thank you Nostradamus........:confused:
     
  10. anonymous

    anonymous Guest

    Boing job
     
  11. anonymous

    anonymous Guest

    I invented ABBOTT LIBRE and the art of posting links Yippeee Look at me
     
  12. anonymous

    anonymous Guest

  13. anonymous

    anonymous Guest

  14. anonymous

    anonymous Guest

    You almost were correct, actually 4 companies (dermatology). Rx will be bought by either Roche, Novartis, or JNJ.
     
  15. anonymous

    anonymous Guest

    AMGEN to merge with GSK